Calgary, AB – January 22, 2025 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, is pleased to advise it has closed the sale of its Belize Property. As previously announced (see prior News Releases dated November 26, December 11, and December 27, 2024 and January 13, [...]

Calgary, AB – June 17, 2024 – TheNewswire – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, advises that it has reached an agreement to issue a total of 4,040,067 common shares at a price of $0.015 per share pursuant to a settlement of accounts payable of [...]

Calgary, AB – TheNewswire - June 7, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, advises that it has closed its previously announced (see News Release of April 12) non-brokered private placement offering of common shares (the “Offering”) and has issued a total of 13,500,000 [...]

Calgary, AB – TheNewswire - April 29, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, is pleased to provide an update on its planned Clinical Trial Application (“CTA”) process.  UI has engaged a new clinical research organization (“CRO”) to complete the process of compiling UI’s [...]

Calgary, AB – TheNewswire - April 22, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, advises that it intends to undertake a non-brokered private placement offering of up to 23,333,333 common shares at a price of $0.015 per share, for proceeds of up to $350,000 [...]

Calgary, AB – TheNewswire - April 12, 2024 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, advises that it intends to undertake a non-brokered private placement offering of up to 30,000,000 common shares at a price of $0.02 per share, for proceeds of up to $600,000 [...]